Core Viewpoint - Zimtu Capital Corp. has acquired 2,400,000 shares of Apex Critical Metals Corp. at a price of $0.06667 per share, increasing its ownership stake in Apex to 10.87% on an undiluted basis and 7.58% on a partially diluted basis [1][2][3] Group 1: Acquisition Details - Zimtu acquired 2,400,000 shares of Apex, which represents an increase in its ownership from 7.75% to 10.87% of the issued and outstanding common shares of Apex on a fully diluted basis [2] - Prior to the acquisition, Zimtu owned 5,547,216 common shares of Apex [2] - Following the acquisition, Zimtu holds a total of 7,947,216 common shares and 278,336 share purchase warrants of Apex [2] Group 2: Regulatory Compliance - The acquisition exceeded 2% of the issued and outstanding common shares of Apex, triggering the requirement to file a news release under National Instrument 62-103 and National Instrument 62-104 [3] - Zimtu will file an early warning report regarding the acquisition, which will include additional information available on Apex's SEDAR profile [3] Group 3: Company Overview - Zimtu Capital Corp. is a public investment issuer focused on long-term capital appreciation for its shareholders, with operations in various sectors including mineral exploration, mining, technology, and life sciences [4] - The company trades on the TSX Venture Exchange under the symbol "ZC" and on Frankfurt under the symbol "ZCT1" [4]

Danaher (NYSE:DHR) FY Conference January 13, 2026 02:15 PM ET Company ParticipantsCasey Woodring - VP and Equity ResearchRainer Blair - CEOCasey WoodringAll right, great. Thank you, everybody, for joining me today. I'm Casey Woodring from the Life Science Tools and Diagnostics team. Welcome to our J.P. Morgan Healthcare Conference. Pleased to be joined by Danaher's CEO, Rainer Blair. Rainer's going to go through the corporate presentation for Danaher, and then we'll do a Q&A session afterwards. Rainer, all ...

Danaher Corporation Rainer Blair, President & CEO J.P. Morgan Healthcare Conference | January 13, 2026 Innovation at the speed of life. Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher's estimated or anticipated financial performance and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward looking" statements within the meaning of the federal secu ...

Core Viewpoint - Corning Incorporated (NYSE:GLW) is recognized as a strong growth stock, with positive sentiment from Wall Street ahead of its fiscal Q4 2025 earnings report expected on January 28 [1] Group 1: Analyst Ratings and Price Targets - J.P. Morgan reiterated a buy rating on Corning without disclosing a price target [1] - Morgan Stanley raised the price target from $82 to $98 while maintaining a Hold rating, indicating a positive outlook on the stock due to the expansion of AI trades benefiting infrastructure stocks [2] Group 2: Financial Expectations - Wall Street anticipates Corning to report a revenue of approximately $4.35 billion for Q4 2025, with a GAAP EPS of $0.62 [3] - Management also expects Q4 revenue to be around $4.35 billion, with core EPS projected between $0.68 and $0.72 [3] Group 3: Business Segments - Corning operates in various sectors including optical communications, display technologies, environmental technologies, specialty materials, and life sciences [3]

Core Insights - The West Lake District has showcased its achievements in the technology sector over the past year and outlined a development blueprint for the upcoming year, focusing on technological innovation [1] - The district emphasizes the construction of the "296X" advanced manufacturing cluster, concentrating on three main industries: artificial intelligence, commercial aerospace, and life health [1] Group 1 - The West Lake District has established a comprehensive support system for enterprises, providing assistance from the initial innovative idea to technology research and development, result transformation, and industrialization [1] - The district has facilitated partnerships between enterprises and high-level platforms, gathering 25 national key laboratories, 72 provincial key laboratories, and 7 provincial new-type research institutions [2] - A new action plan for "Innovative West Lake" has been released, aiming to enhance innovation capabilities through policy support, talent cultivation, and research breakthroughs [2] Group 2 - The district has published a list of application scenario opportunities, which includes 10 scenarios covering artificial intelligence, life health, new consumption, and infrastructure [2] - Since the establishment of the scenario innovation center, the West Lake District has released 43 application scenarios and has organized over 340 collaborative projects benefiting more than 500 enterprises and organizations [2]

Group 1 - Hedge funds sold more U.S. healthcare stocks than they bought for the first time in 14 weeks, indicating a shift in market sentiment as expiring subsidies create uncertainty [1][3] - Approximately 24 million Americans purchase health insurance through the Affordable Care Act, with subsidies set to expire on December 31 unless Congress intervenes, potentially leading to increased costs for consumers [2] - Hedge funds were net sellers of healthcare providers, services, pharmaceuticals, and biotech firms, with short positions significantly outnumbering long positions by more than eight to one, reflecting a bearish outlook [3] Group 2 - Rising healthcare costs and consumer prices are contributing to public discontent, which may impact the upcoming 2026 midterm elections [4] - A bill backed by House Republicans aims to cut premiums for some while reducing subsidies and increasing costs for others, set to take effect in January 2027, shortly after the elections [4] - In November, telehealth firm Him & Hers and scientific instrument maker Bruker emerged as top short picks among mid-sized U.S. stocks, indicating a focus on potential declines in these companies [5]

亚杰新任会长、清科集团创始人董事长、清科控股董事长兼CEO倪正东代表亚杰在年会上致欢迎词，他重点强调了亚杰未来的三项核心工作：一是扩容 优质圈层，凝聚多元力量。吸引更多北京高校的优秀企业家、创业者，打造更包容多元的创业圈层；二是锚定科创赛道，紧扣时代脉搏。重点围绕人工智 能、生命科学和硬科技领域，汇聚前沿创新力量；三是拓展发展边界，赋能全球布局。依托亚杰20多年积累的近千名优秀企业资源，推动企业家们既要 "Go Local" 深耕国内市场，更要 "Go Global" 拓展海外版图，在更广阔的舞台上实现价值增长。 活动现场还邀请了中国经济体制改革研究会副会长、经济学家樊纲，清华大学集成电路学院院长尹首一，依文集团董事长夏华分别担任年会经济学家、科 学家、商业领袖演讲嘉宾带来主题分享，亚杰常务副会长兼秘书长郭基梅向与会嘉宾介绍了亚杰的基本情况和战略布局，摇篮计划16期学员、适创科技总 裁郭志鹏作为学员代表分享在创业中的坚守与探索、挑战与成就。 12月14日，中关村论坛系列活动——"破局成长——杰出企业家成长促进论坛暨亚杰第21届年会"在北京中关村国家自主创新示范区展示中心顺利召开，本 次活动由北京市科学技术委员 ...

Core Viewpoint - Restart Life Sciences Corp. has successfully closed the over-subscribed second tranche of its non-brokered private placement, raising a total of CDN$1,130,000, exceeding its initial target of CDN$1,000,000 due to high investor interest [1]. Group 1: Private Placement Details - The second tranche of the private placement involved the issuance of 6,300,000 units at a price of CDN$0.10 per unit, with each unit comprising one common share and one transferable common share purchase warrant [2]. - Each warrant allows the holder to purchase an additional common share for one year at a price of CDN$0.10 per share [2]. - The company also issued 132,000 non-transferable finder warrants to eligible finders, with similar terms as the purchase warrants [3]. Group 2: Use of Proceeds - The proceeds from the private placement will be allocated towards health food trials, potential acquisitions, and general working capital [4]. - All securities issued under the placement are subject to a hold period of four months and one day, expiring on April 18, 2026 [4]. Group 3: Company Overview - Restart Life Sciences Corp. is a Canadian-based life sciences company listed on the Canadian Securities Exchange [5].

With a market cap of $9.1 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells reagents, instruments, and services for research, diagnostics, and bioprocessing markets. The company operates through two segments: Protein Sciences and Diagnostics and Spatial Biology. Companies valued less than $10 billion are generally classified as “mid-cap” stocks, and Bio-Techne fits this criterion perfectly. The company’s offerings support applications ranging ...

Core Insights - The healthcare and life sciences industry is facing a challenging political and economic environment, with a 9% decrease in optimism compared to the previous year [1][8] - Key legislation is expected to impact supply chain and drug costs, with significant concerns about out-of-pocket costs for patients and supply chain disruptions [4] - Artificial Intelligence (AI) is identified as a crucial area for investment, with 59% of respondents planning to increase their budget for AI in 2026 [5] Political and Regulatory Challenges - Industry leaders are divided on the impact of President Trump's administration, with 51% viewing it positively and 49% negatively [4] - 64% of respondents believe the One Big Beautiful Bill Act will raise out-of-pocket costs for patients, while 56% anticipate increased supply chain disruptions due to the Most Favored Nation policy [4] Artificial Intelligence Development & Usage - 59% of industry leaders plan to allocate more budget to AI and large-language models in 2026 [5] - AI is expected to be implemented across various functions, including internal content development (41%), internal operations (38%), and financial analysis (37%) [5] - In communications, AI is seen as offering significant opportunities in social and digital communications (63%) and media engagement (48%) [5] Cybersecurity Concerns - 47% of respondents feel their organizations are vulnerable to cyber incidents [6] - Only 60% have a crisis communications plan in place, a decrease from 68% in 2025 [6] Transactions & Capital Markets Activity - 65% of respondents expect higher M&A activity in 2026, but only 54% are optimistic about increased IPO activity, a 7% drop from 2025 [7] - The fundraising environment is anticipated to be challenging, with only 28% believing it will be easier to raise capital in 2026 [7]